Evidence map›Paper›PMID 42893475›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Therapeutic Peptide-Programmed Liquid-Crystalline Topology Switching for pH-Gated Postoperative Cancer Immunotherapy.

Yan Yan, Bin Chen, Yanqing Wang, Yuxi Hou, Zhenlin Ma, Zini Yang, Xia Yin, Yiling Chen, Litao Huang, Menghan Cai and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yan YanSchool of Pharmacy and Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology, Macau, China.ORCID https://orcid.org/0009-0002-2019-9996
Bin ChenLivzon Pharmaceutical Group Inc., National Engineering Research Center of Microsphere Technology for Controlled-Release Drug Delivery, Zhuhai, China.
Yanqing WangLivzon Pharmaceutical Group Inc., National Engineering Research Center of Microsphere Technology for Controlled-Release Drug Delivery, Zhuhai, China.
Yuxi HouSchool of Pharmacy and Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology, Macau, China.ORCID https://orcid.org/0009-0008-3589-5859
Zhenlin MaSchool of Pharmacy and Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology, Macau, China.
Zini YangLivzon Pharmaceutical Group Inc., National Engineering Research Center of Microsphere Technology for Controlled-Release Drug Delivery, Zhuhai, China.
Xia YinSchool of Pharmacy and Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology, Macau, China.ORCID https://orcid.org/0000-0003-0463-2067
Yiling ChenSchool of Pharmacy and Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology, Macau, China.ORCID https://orcid.org/0009-0000-6666-4748
Litao HuangSchool of Pharmacy and Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology, Macau, China.
Menghan CaiSchool of Pharmacy and Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology, Macau, China.
Xinlin LiuSchool of Pharmacy and Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology, Macau, China.
Yi Zhun ZhuSchool of Pharmacy and Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology, Macau, China.ORCID https://orcid.org/0000-0001-7700-8041
Li YeSchool of Pharmacy and Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology, Macau, China.ORCID https://orcid.org/0000-0001-7048-6024

Funding

Macao Science and Technology Development Fund FDCT 0013/2026/RIB1Macao Science and Technology Development Fund FDCT 0019/2024/RIA1Macao Science and Technology Development Fund FDCT 0148/2022/A3
6 · The paper itself

Abstract

Stimuli-responsive depots for postoperative cancer therapy often treat therapeutic payloads as passive cargo, resulting in premature leakage and limited on-demand activation. Herein, we report a therapeutic peptide-programmed liquid-crystalline depot in which the Vpr-derived antitumor peptide (VDAP) functions simultaneously as an immunotherapeutic effector and a supramolecular topology regulator. At physiological pH, cationic α-helical VDAP was electrostatically anchored by oleic acid-containing lipid domains, reinforcing a compact inverse hexagonal (H

Indexed as

immunogenic cell deathliquid‐crystalline depotspH‐gated releasepostoperative cancer immunotherapytherapeutic peptidestopological phase transitions

Identifiers

PMID42893475
PMCPMC13676987

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.